EU/3/16/1789 - orphan designation for treatment of sickle cell disease

synthetic human hepcidin

Overview

On 18 November 2016, orphan designation (EU/3/16/1789) was granted by the European Commission to EMAS Pharma Limited, United Kingdom, for synthetic human hepcidin for the treatment of sickle cell disease.

The sponsorship was transferred to Cogas Pharma Limited, Ireland, in July 2017 and subsequently to La Jolla Pharmaceutical II BV, Netherlands, in March 2018.

Please note that this product was withdrawn from the Union Register of orphan medicinal products in May 2022 on request of the Sponsor.

What is sickle cell disease?

Sickle cell disease is a genetic disease in which the red blood cells become rigid and sticky, and change from being disc-shaped to being crescent-shaped (like a sickle). The change in shape is caused by the presence of an abnormal form of haemoglobin, the protein in red blood cells that carries oxygen around the body. In patients with sickle cell disease, the abnormal red blood cells attach to other blood cells and to the walls of blood vessels and block them, restricting the flow of oxygen-rich blood to the internal organs such as the heart, lungs and spleen. Because the abnormal red blood cells have a shorter life span, they release haemoglobin into the blood circulation rather than carrying it to the organs where it is needed. As a result, patients experience severe pain as well as repeated infections and anaemia (low red blood cell counts).

Sickle cell disease is a severe disease that is long-lasting and may be life-threatening because of damage to the heart and the lungs, anaemia and infections.

What is the estimated number of patients affected by the condition?

At the time of designation, sickle cell disease affected approximately 2 in 10,000 people in the European Union (EU). This was equivalent to a total of around 103,000 people*, and is below the ceiling for orphan designation, which is 5 people in 10,000. This is based on the information provided by the sponsor and the knowledge of the Committee for Orphan Medicinal Products (COMP).

---

*Disclaimer: For the purpose of the designation, the number of patients affected by the condition is estimated and assessed on the basis of data from the European Union (EU 28), Norway, Iceland and Liechtenstein. This represents a population of 513,700,000 (Eurostat 2016).

What treatments are available?

At the time of designation, the only medicine authorised in the EU to treat sickle cell disease was hydroxycarbamide. The main treatment for sickle cell disease was blood transfusion. This was usually combined with 'iron chelators' (medicines used to reduce iron overload, high iron levels in the body caused by repeated blood transfusions), which are necessary in patients with long-term anaemias such as sickle cell disease. In some cases, haematopoietic (blood) stem cell transplantation was used. This is a procedure where the patient's bone marrow is cleared of cells and replaced by stem cells from a donor to form new bone marrow that produces healthy blood cells containing normal haemoglobin.

The sponsor has provided sufficient information to show that the medicine might be of significant benefit for patients with sickle cell disease because early studies showed that it may reduce iron overload associated with the condition, and this may be beneficial for patients with sickle cell disease. This assumption will need to be confirmed at the time of marketing authorisation, in order to maintain the orphan status.

How is this medicine expected to work?

Patients with sickle cell disease often suffer from iron overload. This medicine is a synthetic copy of the natural liver hormone hepcidin, which regulates the levels of iron in the body. Hepcidin reduces the amount of iron in the blood by blocking absorption of iron from food and stopping the release of iron from iron-storage cells. The medicine is therefore expected to correct the iron overload and prevent organ damage due to iron accumulation in patients with sickle cell disease.

What is the stage of development of this medicine?

The effects of the medicine have been evaluated in experimental models.

At the time of submission of the application for orphan designation, clinical trials with the medicine in patients with sickle cell disease were ongoing.

At the time of submission, the medicine was not authorised anywhere in the EU for sickle cell disease. Orphan designation of the medicine had been granted in the United States for sickle cell disease.

In accordance with Regulation (EC) No 141/2000 of 16 December 1999, the COMP adopted a positive opinion on 6 October 2016 recommending the granting of this designation.

Opinions on orphan medicinal product designations are based on the following three criteria:

• the seriousness of the condition;
• the existence of alternative methods of diagnosis, prevention or treatment;
• either the rarity of the condition (affecting not more than 5 in 10,000 people in the EU) or insufficient returns on investment.

Designated orphan medicinal products are products that are still under investigation and are considered for orphan designation on the basis of potential activity. An orphan designation is not a marketing authorisation. As a consequence, demonstration of quality, safety and efficacy is necessary before a product can be granted a marketing authorisation.

Key facts

• Active substance:
  synthetic human hepcidin
• Intended use:
  Treatment of sickle cell disease
• Orphan designation status:
  Withdrawn
• EU designation number:
  EU/3/16/1789
• Date of designation:
  18/11/2016
• Sponsor:

  La Jolla Pharmaceutical II BV; Herengracht 500; 1017 CB Amsterdam; The Netherlands; Tel. [phone]; E-mail: [e-mail]